slides · global inventory
Callout
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 41,369
Current window 33,991-34,020
Pages 1,379
Rows per page 30
Component
33,991-34,020 of 41,369
14
The slide explicitly notes that this is a cross-trial comparison and not a head-to-head study.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · Competitive AnalysisLoop · Cost Of Inaction1 hit
20
Includes a disclaimer about cross-trial comparison limitations.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · Competitive AnalysisLoop · Golden Circle1 hit
22
The slide explicitly notes that these are cross-trial comparisons and not head-to-head results.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · Competitive AnalysisLoop · Golden Circle1 hit
38
The slide uses a step-wise diagram to illustrate dose escalation in a clinical trial setting.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
46
Includes a process flow diagram illustrating the mechanism of action of IMX-110 in tumor microenvironments.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
08
The slide uses a schematic diagram to map specific protein domains to their functional benefits.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · InterestLoop · Logic Chain1 hit
10
The slide uses a combination of bar charts for preclinical cytokine release and a table for clinical outcomes to demonstrate the superiority of NXC-201.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
13
The slide uses a bar chart combined with a data table to highlight safety advantages. It includes a disclaimer about cross-trial comparisons.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
19
The slide uses a grouped bar chart format to highlight clinical superiority. Includes a disclaimer about cross-trial comparisons.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · ActionLoop · David Goliath1 hit
21
The slide explicitly notes that these are cross-trial comparisons and not head-to-head results.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · ActionLoop · David Goliath1 hit
41
Includes a process flow diagram illustrating the mechanism of action of iMX-110 in tumor microenvironments.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
07
Invitae | Results Presentation Deck | 27 slidesInvitae | Results Presentation Deck | 27 slides · Invitae
Conference presentation Investor relations Beat · NeedLoop · Why Now1 hit
22
Includes a table of liquidity metrics and a bar chart showing bond maturity distribution by year.Kering | Fixed Income Presentation Deck | 35 slides · Kering
Deck Investor relations 1 hit
06
Kering | Investor Presentation Deck | 63 slidesKering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations Beat · Situation & Context1 hit
30
EP&L stands for Environmental Profit & Loss. The slide uses a bubble matrix to show impact distribution and a dual-line chart to show intensity reduction.Kering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
09
Includes a mechanism of action diagram, a market data table, and a comparison of current therapy limitations.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
22
Includes a table of prevalence/incidence for various indications and a diagram of the JAK-STAT signaling pathway.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
25
The table displays adverse events occurring in 2 or more patients. Data includes patient counts and percentages for both 'All' and 'Related' adverse events.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
30
The slide uses a split-layout: left side for clinical data results, right side for strategic positioning.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
32
Includes a waterfall plot of cell line dependency and a biological process diagram showing the MDM2-p53 feedback loop.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
39
The slide uses a split-layout to contrast technical mechanism/data (left) with strategic market opportunity (right).Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
01
Larimar Therapeutics | Investor Presentation Deck | 44 slidesLarimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations 1 hit
08
The slide uses a visual comparison of protein structures to explain the mechanism of action.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
20
Larimar Therapeutics | Investor Presentation Deck | 44 slidesLarimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
21
Larimar Therapeutics | Investor Presentation Deck | 44 slidesLarimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
40
Kaplan-Meier survival curve showing efficacy of FXN replacement therapy.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
11
Legend Biotech | Results Presentation Deck | 15 slidesLegend Biotech | Results Presentation Deck | 15 slides · Legend Biotech
Conference presentation Investor relations Beat · Satisfaction1 hit
09
Includes quarterly revenue and operating profit trends, plus key strategic metrics.Lenovo | Results Presentation Deck | 18 slides · Lenovo
Conference presentation Investor relations Beat · KPI OverviewLoop · Logic Chain1 hit
05
The slide uses a comparative structure to highlight the margin difference between GCR (12-15%) and ODR (25-28%).Limbach Holdings | Investor Presentation Deck | 28 slides · Limbach
Pitch deck Investor relations Beat · Problem1 hit
09
The slide highlights the physical infrastructure and production capability.Lion Electric | Investor Presentation Deck | 30 slides · Lion Electric
Pitch deck Investor relations Beat · ProductLoop · Voice Of Customer1 hit